<rows>
  <row id="819366">
    <langcode>en</langcode>
    <name>button-download-data</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/fact-book/general/Download_Data_button.png</field_media_image>
    <field_accessible_version>Download the Data</field_accessible_version>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1088966">
    <langcode>en</langcode>
    <name>Tumor Diffusion of Nanoparticles</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/tumor-diffusion-nanoparticles.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>This image shows micelle-based nanoparticles (red) that have moved beyond the blood vessels (green) of a tumor in a mouse model of ovarian cancer. The nanoparticles diffused throughout the entire tumor within 48 hours of injection, suggesting excellent tumor-penetration capability.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088969">
    <langcode>en</langcode>
    <name>Observation of Nanotube Delivery</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/observation-nanotube-delivery.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>This image shows blood vessels (light blue) infiltrating brain cancer (purple) in a live mouse. The high resolution achieved here enables single cancer cells to be visualized and allows direct observation and quantification of nanoparticle delivery and their targeting cancer cells.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088970">
    <langcode>en</langcode>
    <name>Nanoparticles in Pancreatic Tumor</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/nanoparticles-pancreatic-tumor.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>This image shows magnetic iron nanoparticles that target cells with IGF-1R receptors, and are conjugated to a chemotherapy drug (dark blue). In the tumor stroma of a mouse model of pancreatic cancer, the nanoparticles delivered the chemotherapy to tumor-associated macrophages expressing IGF-1R (red) and CD68 (green). These magnetic iron nanoparticles are theranostic &ndash; capable of both diagnostic and therapeutic functions.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088973">
    <langcode>en</langcode>
    <name>Kircher</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/Kircher.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Principle of a triple-modality MRI-photoacoustic-Raman nanoparticle for clinical use. The nanoparticle is injected intravenously. In contrast to small molecule contrast agents that wash out of the tumor quickly, the nanoparticles are stably internalized within the brain tumor cells, allowing the whole spectrum from preoperative MRI for surgical planning to intraoperative imaging to be performed with a single injection. T1-weighted MRI depicts the outline of the tumor due to the T1-shortening effect of the gadolinium. During the surgery, photoacoustic imaging with its greater depth penetration and 3D imaging capabilities can be used to guide the gross resection steps, while Raman imaging can guide the resection of the microscopic tumor at the resection margins. Raman would be used for rapid conformation of clean margins in the operating room instead of the time-consuming analysis of frozen sections.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088974">
    <langcode>en</langcode>
    <name>Bradbury</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/Bradbury.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Present and future of NanoOncology Image-guided Surgical Suite. Preoperative conventional imaging tools are used to screen for disease and inform optically- driven minimally-invasive and open surgical procedures. Clinically available particle platforms can be monitored in real-time using portable multichannel camera systems. Representative translational probes and devices for future clinical use are also shown. In the future, the operating surgeon will select suitable probe-device combinations for specific indications, and be provided with structural, functional, and/or molecular-level data regarding ssue status for further treatment management.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088975">
    <langcode>en</langcode>
    <name>DEAL Barcode Assay to Enable Precision Medicine</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/deal-barcode.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>The image shows the DEAL (DNA-encoded antibody library) barcode assay, a high density information test for human blood proteins designed to show the individual identities of every human disease, allowing for personalized medicine.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088977">
    <langcode>en</langcode>
    <name>Multiplexed Blood Protein Profiling </name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/multiplexed-blood-protein-profiling.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Imaged here is a microfluidic magneto-nano chip with 8 by 8 sensors arrays and 8 microfluidic channels. These chips are being developed to monitor protein profiles in blood samples from cancer patients to improve therapeutic effectiveness.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088978">
    <langcode>en</langcode>
    <name>Nanosensors in Breast Tumor</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/nanosensor-breat-cancer.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Here a fluorescent nanosensor (cyan) and a chemical with anti-cancer activity (dichloroacetic acid) were injected into the blood vessels (red) of a mouse implanted with human breast cancer (green). This image shows that the nanosensor detects the presence of dichloroacetic acid near the tumor.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088984">
    <langcode>en</langcode>
    <name>Vaccine-Based Immunotherapy from Novel Nanoparticle Systems</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/vaccine-based-immunotherapy.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>This scanning electron microscope image shows dendritic cells, pseudo-colored in green, interacting with T cells, pseudo-colored in pink. The dendritic cells internalize the particles, process the antigens, and present peptides to T cells to direct immune responses.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088985">
    <langcode>en</langcode>
    <name>Huang-Figure</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/Huang.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Depiction of the complex pathway involved in cancer immunotherapy. Nanoparticle delivery vehicles can play a role at multiple points along this pathway.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1088990">
    <langcode>en</langcode>
    <name>Label-free Detection of Cancer Biomarkers with Ultrasensitive Mass Detection</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/detection-cancer-biomarkers-article.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>The image is an electron micrograph of a suspended microchannel resonant (SMR) mass sensor under development by researchers at the MIT-Harvard CCNE/CNPP. This sensor is being developed for label-free detection of cancer biomarkers.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1090634">
    <langcode>en</langcode>
    <name>OCNR-Alliance-Companies</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/OCNR-Alliance-Companies.PNG</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Numerous companies have been formed by Alliance PI's over the years of the program. These are listed in this graphic by type of product being developed and company name.</p>
</div>]]></field_caption>
    <field_display_enlarge>1</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1090836">
    <langcode>en</langcode>
    <name>Piotr_staffimage</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/piotr.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1090837">
    <langcode>en</langcode>
    <name>Scott-Mcneil-staffimage</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/s-mcneil.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1090839">
    <langcode>en</langcode>
    <name>ChrisHartshorn-staffimage</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/hartshorn.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1090840">
    <langcode>en</langcode>
    <name>Christina-staffimage</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CHLIU-pic.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1090883">
    <langcode>en</langcode>
    <name>Stanford_CCNE</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CCNE-TD_Overall.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Stanford CCNE Overview and Project Focus Diagram</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Stanford University</field_credit>
  </row>
  <row id="1090884">
    <langcode>en</langcode>
    <name>CCNE-Stanford-Project1</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CCNE-TD_P1.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Stanford CCNE Project 1 Overview</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Stanford University</field_credit>
  </row>
  <row id="1090885">
    <langcode>en</langcode>
    <name>CCNE-Standford-Project2</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CCNE-TD_P2.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Stanford CCNE Project 2 Overview</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Standford University</field_credit>
  </row>
  <row id="1090886">
    <langcode>en</langcode>
    <name>CCNE-Standford-Project3</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CCNE-TD_P3.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Stanford CCNE Project 3 Overview</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Stanford University</field_credit>
  </row>
  <row id="1090984">
    <langcode>en</langcode>
    <name>OSU-IRCN</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/IRCN-OSU.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091023">
    <langcode>en</langcode>
    <name>CCNE-Washu</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/WashU_Overview.PNG</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Washington University CCNE Overview and Project Focus Diagram</p>
</div>]]></field_caption>
    <field_display_enlarge>1</field_display_enlarge>
    <field_credit>Credit: Washington University</field_credit>
  </row>
  <row id="1091024">
    <langcode>en</langcode>
    <name>CCNE-Washu-P1</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/WashU_P1.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Project 1: Small molecule cMYC-inhibitors are incorporated as lipase labile prodrugs in VLA-4-directed Micelles (&lt;20nm).&nbsp; 1) Micelles home beyond the vasculature, penetrate into the extravascular space and bind the alpha 4 beta 1 (VLA-4) cell surface receptor over expressed by multiple myeloma (MM). 2) The micelle forms a hemifusion complex with the MM outer cell membrane and lipid-complexed cMYC prodrug passes into the target cell. 3) The cMYC-prodrug (cMYC-PD) flips from the outer to inner cell membrane, which is contiguous with all of the intracellular membranes of the cell except the mitochondria. 4. Intracellular lipases liberate the cMYC active drug from the inactive lipid prodrug complex, which becomes available to interact with cMYC transcription factor (TF) in the cytosol (4b).&nbsp; 4a Uncomplexed cMYC TF can penetrate into the nucleus, complex with MAX transcription factor to form a heterodimer that interacts with the E-box of DNA to stimulate cell proliferation (5a). cMYC inhibited by the free Myc-inhibitor in the cytosol can enter the nucleus but cannot complex with MAX. This disrupts MM cell proliferation and promotes MM apoptosis.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091025">
    <langcode>en</langcode>
    <name>CCNE-Washu-P2</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/WashU_P2.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Washington University CCNE Project 2 Overview</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Washington University</field_credit>
  </row>
  <row id="1091026">
    <langcode>en</langcode>
    <name>CCNE-Washu-P3</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/WashU_P3.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Washington University CCNE Project 3 Overview</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Washington University</field_credit>
  </row>
  <row id="1091042">
    <langcode>en</langcode>
    <name>CCNE-NWU</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/NWUCCNEOverview.png</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Northwestern University CCNE Overview and Project Focus Diagram</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Northwestern University</field_credit>
  </row>
  <row id="1091055">
    <langcode>en</langcode>
    <name>CNTC-UT</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/UT_MDAnder_T32.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091204">
    <langcode>en</langcode>
    <name>IRCN-case-western</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/IRCN-case western.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091245">
    <langcode>en</langcode>
    <name>Nanotech Image</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/nanotech-article.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Nanoscale devices are one hundred to ten thousand times smaller than human cells.&nbsp; The depiction displays this scale in size.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: National Cancer Institute</field_credit>
  </row>
  <row id="1091247">
    <langcode>en</langcode>
    <name>CNTC-JHU</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CNTC-JHU.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091248">
    <langcode>en</langcode>
    <name>CCNE Organization Chart</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CCNE-Organization-Chart.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>University of North Carolina CCNE Overview and Project Focus Diagram</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: University of North Carolina</field_credit>
  </row>
  <row id="1091249">
    <langcode>en</langcode>
    <name>UCLA-CSMC</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/UO1-UCLA-CSMC.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091250">
    <langcode>en</langcode>
    <name>Harvard-Weissleder</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/Weissleder.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091251">
    <langcode>en</langcode>
    <name>Emory IRCN</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/Emory-IRCN.PNG</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091269">
    <langcode>en</langcode>
    <name>NWU-CNTC</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/NWU-CNTC.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091270">
    <langcode>en</langcode>
    <name>UNC-CNTC</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CNTC-UNC.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091316">
    <langcode>en</langcode>
    <name>CCNE-NWUP1</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/NWUCCNEP1_a.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Northwestern University CCNE Project 1 Overview</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Northwestern University</field_credit>
  </row>
  <row id="1091317">
    <langcode>en</langcode>
    <name>CCNE-NWU-P2</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/NWUCCNEP2_a.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Northwestern University CCNE Project 2 Overview</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Northwestern University</field_credit>
  </row>
  <row id="1091318">
    <langcode>en</langcode>
    <name>CCNE-NWUP3</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/NWUCCNEP3.png</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Northwestern University CCNE Project 3 Overview</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: Northwestern University</field_credit>
  </row>
  <row id="1091323">
    <langcode>en</langcode>
    <name>IRCN - UCDavis</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/Lam_UCDavis_IRCN.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091324">
    <langcode>en</langcode>
    <name>IRCN - UCLA</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/UCLA_IRCN_Nel_Meng.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091598">
    <langcode>en</langcode>
    <name>Alliance_logo</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/AllianceLogo.png</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1091800">
    <langcode>en</langcode>
    <name>CNTC-UC San Diego</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/CCNE-UCSanDiego.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1093979">
    <langcode>en</langcode>
    <name>Stanford CNTC</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/infographics/StanfordCNTCgraphic.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
  <row id="1096437">
    <langcode>en</langcode>
    <name>Cdot Cy5 5</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/illustrations-graphics/Cdot-Cy5-5-article.jpg</field_media_image>
    <field_accessible_version>Overview displaying Cornell dot nanoparticle and its multiple use cases. </field_accessible_version>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Project 3 version of platform technology, the C-dot nanoparticle, incorporating novel radiohalogens to deliver highly concentrated doses of radiotherapy to melanomas and brain tumors.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: MSKCC</field_credit>
  </row>
  <row id="1096438">
    <langcode>en</langcode>
    <name>CMCTN Overview</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/illustrations-graphics/CMCTN-overview-figure-article.jpg</field_media_image>
    <field_accessible_version>Project 3 version of platform technology, the C-dot nanoparticle.</field_accessible_version>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Center overview displaying Cornell dot nanoparticle and its multiple use cases.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: MSKCC</field_credit>
  </row>
  <row id="1097028">
    <langcode>en</langcode>
    <name>CalTech CCNE Overall</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/illustrations-graphics/Overall-article.jpg</field_media_image>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Overall goals of the NanoSystems and Biology Cancer Center (NSBCC) include bringing novel tools and biological insight for treating glioblastoma multiforme and metastatic melanomas. The novel tools include a set of single cell analytics, nanotechnology based devices and delivery systems as well as novel animal models from patient derived tumor samples.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: CalTech CCNE</field_credit>
  </row>
  <row id="1097034">
    <langcode>en</langcode>
    <name>CalTech CCNE Project 1</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/illustrations-graphics/caltech-ccne-project1-article.png</field_media_image>
    <field_accessible_version>Project 1 focus is on nanoparticle therapies for delivery across the blood-brain barrier (BBB). </field_accessible_version>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>Project 1's focus is on nanoparticle therapies for delivery across the blood-brain barrier (BBB). Delivery across this barrier is traditionally one of the toughest biological barriers to deliver therapy the other side of. Project 1 is developing a novel nanoparticle (NP) system to target BBB, cross BBB, and ultimately deliver chemotherapeutics to the tumor. The figure above depicts the general strategy to develop the platform and novel animal models as well as testing of in vivo efficacy.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: CalTech CCNE</field_credit>
  </row>
  <row id="1097035">
    <langcode>en</langcode>
    <name>CalTech CCNE Project 2</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/illustrations-graphics/caltech-ccne-project2-article.png</field_media_image>
    <field_accessible_version>The Project 2 focus is on development of Protein Catalyzed Capture (PCC) Agents as cancer drugs.</field_accessible_version>
    <field_caption><![CDATA[<div class="rxbodyfield">
<p>The Project 2 focus is on development of Protein Catalyzed Capture (PCC) Agents as cancer drugs. The primary goal is to enable more specific definition of tumor tissue/cell binding sites that will enable novel therapeutics. The figure above displays one of several aspects of this project utilizing experimentally defined parameters to guide novel molecular dynamics simulation of these sites.</p>
</div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: CalTech CCNE</field_credit>
  </row>
  <row id="1097036">
    <langcode>en</langcode>
    <name>CalTech CCNE Project 3</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/illustrations-graphics/caltech-ccne-project3-article.png</field_media_image>
    <field_accessible_version>The NSBCC Project 3 he Project 3 focus is on utilizing a new class of nanotechologies towards identifying the matched antigen specificity and T cell receptor a/b gene sequence for each T cell that infiltrates into a tumor.</field_accessible_version>
    <field_caption><![CDATA[<div class="rxbodyfield"><p>The Project 3 focus is on utilizing a new class of nanotechologies towards identifying the matched antigen specificity and T cell receptor a/b gene sequence for each T cell that infiltrates into a tumor. An area overall that will help to identify cancer patient response to immunotherapies, which still represents a major barrier to this therapeutic modality. The figure above represents the general scheme by which this project will develop and correlate these libraries of antigens to T cells for the eventual application of tools that can measure patient response in vivo.</p></div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: CalTech CCNE</field_credit>
  </row>
  <row id="1097037">
    <langcode>en</langcode>
    <name>CalTech CCNE Project 4</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/illustrations-graphics/caltech-ccne-project4-article.png</field_media_image>
    <field_accessible_version>NSBCC's Project 4 focuses upon using novel patient-derived animal models to understand glioblastoma multiforme.</field_accessible_version>
    <field_caption><![CDATA[<div class="rxbodyfield"><p>Project 4 focuses upon using novel patient-derived animal models to understand glioblastoma multiforme (GBM) and its subsequent heterogeneity. The downstream goal is develop and apply this understanding for novel drug combinations and immunotherapeutic response in patients with GBM. The figure above displays the various nanoscale tools being used to understand GBM physiology in these novel animal models and via single-cell analytics.</p></div>]]></field_caption>
    <field_display_enlarge>0</field_display_enlarge>
    <field_credit>Credit: CalTech CCNE</field_credit>
  </row>
  <row id="1113339">
    <langcode>en</langcode>
    <name>Luisa Russell Headshot</name>
    <field_media_image>https://www.cancer.gov/PublishedContent/Images/images/nano/luisa-russell-article.jpg</field_media_image>
    <field_display_enlarge>0</field_display_enlarge>
  </row>
</rows>